Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer ImmunoGlobeNewsWire • 09/13/23
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/03/23
Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth ConferenceGlobeNewsWire • 08/02/23
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”GlobeNewsWire • 06/13/23
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid TumorsGlobeNewsWire • 06/01/23
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/09/23
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking AntibodyGlobeNewsWire • 04/20/23
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023GlobeNewsWire • 04/18/23
Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual SymposiumGlobeNewsWire • 03/30/23
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/28/23
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking AntibodyGlobeNewsWire • 03/21/23
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023GlobeNewsWire • 03/14/23
Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/06/23
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody TherapeuticsGlobeNewsWire • 02/21/23
Sensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership SummitGlobeNewsWire • 02/16/23
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody TherapeuticsGlobeNewsWire • 02/14/23
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking AntibodyGlobeNewsWire • 02/06/23
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid TumorsGlobeNewsWire • 01/05/23
Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)Business Wire • 12/12/22
Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/22/22
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking AntibodyGlobeNewsWire • 11/21/22
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/08/22
